Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study

MLA

Karen Kelly, et al. “Efficacy and Safety of First-Line Avelumab in Patients with Advanced Non-Small Cell Lung Cancer: Results from a Phase Ib Cohort of the JAVELIN Solid Tumor Study.” Journal for ImmunoTherapy of Cancer, vol. 8, no. 2, July 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....60f3e4e880579c8840526fffffb6e7a0&authtype=sso&custid=ns315887.

APA

Karen Kelly, Dongli Zhou, Jaafar Bennouna, Franklin Chen, Guy Jerusalem, John C. Morris, Ding Wang, Claire F. Verschraegen, Marcis Bajars, Edward F. McClay, Neru Munshi, David R. Spigel, Hans Juergen Grote, Janice M. Mehnert, Matthew H. Taylor, James L. Gulley, Nicholas Iannotti, & Charles H. Redfern. (2020). Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study. Journal for ImmunoTherapy of Cancer, 8(2).

Chicago

Karen Kelly, Dongli Zhou, Jaafar Bennouna, Franklin Chen, Guy Jerusalem, John C. Morris, Ding Wang, et al. 2020. “Efficacy and Safety of First-Line Avelumab in Patients with Advanced Non-Small Cell Lung Cancer: Results from a Phase Ib Cohort of the JAVELIN Solid Tumor Study.” Journal for ImmunoTherapy of Cancer 8 (2). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....60f3e4e880579c8840526fffffb6e7a0&authtype=sso&custid=ns315887.